Technical Analysis for AGE - AgeX Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 4.53 -5.63% -0.27
AGE closed down 5.63 percent on Wednesday, February 20, 2019, on 88 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Up Up
See historical AGE trend table...

Date Alert Name Type % Chg
Feb 20 Inside Day Range Contraction 0.00%
Feb 20 Upper Bollinger Band Touch Strength 0.00%
Feb 19 180 Bullish Setup Bullish Swing Setup -5.63%
Feb 19 Pocket Pivot Bullish Swing Setup -5.63%
Feb 19 Above Upper BB Strength -5.63%
Feb 19 Upper Bollinger Band Touch Strength -5.63%
Feb 15 Inside Day Range Contraction 8.11%
Feb 14 20 DMA Support Bullish 4.86%
Feb 14 MACD Bullish Signal Line Cross Bullish 4.86%
Feb 13 Crossed Above 20 DMA Bullish 10.49%

Older signals for AGE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology. Renelon™ is a first-generation iTR product designed to promote scarless tissue repair which AgeX plans to initially develop as a topically-administered device for commercial development through a 510(k) application. In addition to the product candidates in early development, AgeX, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. AgeX also markets Cytiva® comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.
Biotechnology Life Sciences Biology Diseases Stem Cells Cell Biology Tissue Engineering Degenerative Disease Cloning Stem Cell Telomerase
Is AGE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.95
52 Week Low 1.13
Average Volume 111,392
200-Day Moving Average 0.0
50-Day Moving Average 3.8062
20-Day Moving Average 4.1425
10-Day Moving Average 4.276
Average True Range 0.4319
ADX 21.58
+DI 25.4812
-DI 12.0924
Chandelier Exit (Long, 3 ATRs ) 3.5443
Chandelier Exit (Short, 3 ATRs ) 4.9957
Upper Bollinger Band 4.7111
Lower Bollinger Band 3.5739
Percent B (%b) 0.84
BandWidth 27.452022
MACD Line 0.1341
MACD Signal Line 0.0924
MACD Histogram 0.0417
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.00
Resistance 3 (R3) 5.05 4.94 4.92
Resistance 2 (R2) 4.94 4.82 4.92 4.90
Resistance 1 (R1) 4.74 4.75 4.68 4.69 4.87
Pivot Point 4.63 4.63 4.60 4.60 4.63
Support 1 (S1) 4.42 4.50 4.37 4.37 4.19
Support 2 (S2) 4.31 4.43 4.29 4.16
Support 3 (S3) 4.11 4.31 4.14
Support 4 (S4) 4.06